Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alfredo Sanchez Cruz

Endocrinology, Diabetes & Metabolism San Juan, PR Medical Doctor

NPI 1619133857 CMS profile 164206

29 Washington Street, Ashford Medical Ctr Ste 505, San Juan, PR 00907

Open in the dashboard

General payments

$13,491

164 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alfredo Sanchez Cruz of San Juan, PR is reported in the CMS Open Payments database as having received $13,491 across 164 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $861 9
2024 General $349 9
2023 General $750 21
2022 General $687 33
2021 General $592 19
2020 General $1,370 7
2019 General $8,883 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alfredo Sanchez Cruz
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Alfredo Sanchez Cruz were reported at $861. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Alfredo Sanchez Cruz Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $8,883 $494 $123–$2,253 $163
2020 $1,370 $335 $85–$1,841 $114
2021 $592 $398 $88–$1,981 $132
2022 $687 $364 $88–$1,568 $149
2023 $750 $420 $113–$1,614 $160
2024 $349 $440 $121–$1,646 $164
2025 $861 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sanofi-Aventis U.S. LLC $6,783 15 payments
  2. Janssen Pharmaceuticals, Inc $2,422 13 payments
  3. AstraZeneca Pharmaceuticals LP $1,340 41 payments
  4. Medtronic, Inc. $712 6 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $615 24 payments
  6. Novo Nordisk Inc $615 21 payments
  7. Merck Sharp & Dohme Corporation $280 11 payments
  8. Eli Lilly Export S.A. Puerto Rico Branch $270 16 payments
  9. Lilly USA, LLC $119 1 payment
  10. Amgen Inc. $113 6 payments
  11. Other $221 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,230 6 payments
  2. Food and Beverage $4,760 149 payments
  3. Consulting Fee $1,870 1 payment
  4. Travel and Lodging $615 5 payments
  5. Education $16 3 payments
Products named General payments · program years 2019–2025
  1. SOLIQUA 100/33 $4,955 7 payments
  2. INVOKANA $2,322 12 payments
  3. TOUJEO $1,272 2 payments
  4. FARXIGA $975 26 payments
  5. MINIMED 780G $712 6 payments
  6. LOKELMA $470 17 payments
  7. JARDIANCE $445 19 payments
  8. RYBELSUS $373 15 payments
  9. SOTAGLIFLOZIN $300 1 payment
  10. Ozempic $299 15 payments
  11. Other $3,228 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 63 drugs

Part D claims

7,253

Median for General Practice: 1,105

Drug cost

$2,461,300

Median for General Practice: $48,734

Branded share of claims

68.1%

Median for General Practice: 17.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 456 $456,972
Ozempic Semaglutide Brand 257 $410,088
Jardiance Empagliflozin Brand 502 $344,002
Mounjaro Tirzepatide Brand 205 $227,013
Farxiga Dapagliflozin Propanediol Brand 292 $203,925
Synjardy Xr Empagliflozin/Metformin Hcl Brand 124 $89,322
Januvia Sitagliptin Phosphate Brand 115 $83,743
Synthroid Levothyroxine Sodium Brand 1,373 $82,668
Trijardy Xr Empaglifloz/Linaglip/Metformin Brand 108 $78,206
Glyxambi Empagliflozin/Linagliptin Brand 100 $71,751

The 10 drugs with the highest cost, of 63 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$2,772

Medicare's payments for the services billed

Medicare patients

17

Average age 75

Services billed

27

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LOKELMA
  • AstraZeneca Pharmaceuticals LP $98
$98 — —
Korlym
  • Corcept Therapeutics $50
$50 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $45
$45 292 —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $34
$34 — —
TOUJEO
  • SANOFI-AVENTIS U.S. LLC $34
$34 62 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record